BACKGROUND: Clinical trial costs may be reduced by identifying enriched subpopulations of patients with favorable risk profiles for the events of interest.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
However, increased selectivity affects accrual rates, with uncertain impact on clinical trial cost.
METHODS: We conducted a secondary analysis of Southwest Oncology Group (SWOG) 8794 randomized trial of adjuvant radiotherapy for high-risk prostate cancer. The primary endpoint was metastasis-free survival (MFS), defined as time to metastasis or death from any cause (competing mortality). We used competing risks regression models to identify an enriched subgroup at high risk for metastasis and low risk for competing mortality. We applied a cost model to estimate the impact of enrichment on trial cost and duration.
RESULTS: The treatment effect on metastasis was similar in the enriched subgroup (HR, 0.42; 95% CI, 0.23-0.76) compared to the whole cohort (HR, 0.50; 95% CI, 0.30-0.81) while the effect on competing mortality was not significant in the subgroup or the whole cohort (HR 0.70; 95% CI 0.39-1.23, vs. HR 0.94; 95% CI, 0.68-1.31). Due to the higher incidence of metastasis relative to competing mortality in the enriched subgroup, the treatment effect on MFS was greater in the subgroup compared to the whole cohort (HR 0.55; 95% CI 0.36-0.82, vs. HR 0.77; 95% CI, 0.58-1.01). Trial cost was 75% less in the subgroup compared to the whole cohort ($1.7million vs. $6.8million), and the trial duration was 30% shorter (8.4 vs. 12.0years).
CONCLUSION: Competing event enrichment can reduce clinical trial cost and duration, without sacrificing generalizability.
Zakeri K, Rose BS, D'Amico AV, Jeong JH, Mell LK. Are you the author?
Department of Radiation Medicine and Applied Sciences, University of California San Diego, United States; Harvard Radiation Oncology Program, Harvard Medical School, Boston, United States; Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, United States; Department of Biostatistics, University of Pittsburgh, United States.
Reference: Radiother Oncol. 2015 Apr 6. pii: S0167-8140(15)00157-7.